The Medicinal, Therapeutic, and Enlightening Effects of Magic Mushrooms.

Contrary to popular belief, the consumption of hallucinogenic psilocybin-bearing mushrooms has scientifically shown a variety of therapeutic and medicinal effects, and some would argue it can help one reach states of spiritual enlightenment and resolve chronic symptoms of depression, anxiety, and even addiction. Extremely high frequencies of thought are the function of a stimulated pineal gland and deeply interconnected brain. The increased neuronal scaffolding our brains experience during hallucinogenic experiences is a direct function of our neural pathways becoming less discriminate and more divergent; two ways of thinking that can give an individual a “different perspective” on certain issues (often internal) that are not blatant to their conscious self.

Other than an increased perceptual field, deep feelings of oneness and empathy, and ego-death (dissolution of sedimentations associated with the thinking-self in order to reconnect with the universal self), the consumption of magic mushrooms is clinically associated with NGF biosynthesis, which is the creation of new healthy brain cells, as well as neuroplasticity; the ability of the brain to reorganize and regenerate synaptic activity. These two among various other empirically proven scientific benefits of magic mushrooms deem them undoubtedly safe, and for some, arguably a necessary form of treatment. Thus regardless of their federal demonization, there is nothing that can dispel hallucinogenic mushrooms as a proven treatment to neuroticism, chronic stress & anxiety, depression, introversion, and countless other mental health conditions that we as a society have systematically been made so vulnerable to.

  1. Psilocybin is a safe, effective, and non-addictive anti-anxiolytic and anti-depressant, so its no wonder it is a highly regulated and criminalized substance. https://www.independent.co.uk/life-style/health-and-families/psilocybin-from-magic-mushrooms-eases-anxiety-and-depression-in-cancer-patients-a7465191.html
  1. Psychedelic-assisted treatment can produce rapid, robust, and sustained improvements in cancer-related psychological and existential distress.

https://www.ncbi.nlm.nih.gov/pubmed/30102082

2) Psychedelics regulate inflammatory pathways via novel mechanisms, and may represent a new and exciting treatment strategy for several inflammatory disorders.

https://www.ncbi.nlm.nih.gov/pubmed/30102081

3) Psilocybin and LSD reduced anxiety and depression in cancer patients and symptoms of alcohol and tobacco dependence, and ayahuasca reduced depression symptoms in treatment-resistant depression.

https://www.ncbi.nlm.nih.gov/pubmed/30102078

4) Psilocybin may have some efficacy as an alternative agent to manage mental health conditions.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007659/

5) Neuroticism scores significantly decreased while Extraversion increased following psilocybin therapy.

https://www.ncbi.nlm.nih.gov/pubmed/29923178

6) Psilocybin in magic mushrooms can stimulate the growth of new brain cells (NEUROGENESIS). PSOP facilitates extinction of the classically conditioned fear response, and this, and similar agents, should be explored as potential treatments for post-traumatic stress disorder and related conditions.

https://www.ncbi.nlm.nih.gov/pubmed/23727882

7) Psilocybin can alleviate deleterious changes in the brain caused by chronic stress leading to restoration of homeostatic brain fibrinolytic capacity leading to euthymia.

https://www.ncbi.nlm.nih.gov/pubmed/28236848

8) Evidence that psilocybin enhances autobiographical recollection implies that it may be useful in psychotherapy either as a tool to facilitate the recall of salient memories or to reverse negative cognitive biases.

https://www.ncbi.nlm.nih.gov/pubmed/22282432

9) These results demonstrate that acute treatment with psilocybin decreased amygdala reactivity during emotion processing and that this was associated with an increase of positive mood in healthy volunteers. These findings may be relevant to the normalization of amygdala hyperactivity and negative mood states in patients with major depression.

https://www.ncbi.nlm.nih.gov/pubmed/24882567

10)  Together, the present results provide a comprehensive account of the effects of psilocybin on dynamical behavior in the human brain at a macroscopic level and may have implications for our understanding of the unconstrained, hyper-associative quality of consciousness in the psychedelic state.

https://www.ncbi.nlm.nih.gov/pubmed/24989126

11) These results strongly imply that the subjective effects of psychedelic drugs are caused by decreased activity and connectivity in the brain’s key connector hubs, enabling a state of unconstrained cognition.

https://www.ncbi.nlm.nih.gov/pubmed/22308440

12) These results provide systematic evidence for the direct association of a specific spatiotemporal neuronal mechanism with spiritual experiences and enhanced insight into life and existence. The identified mechanism may constitute a pathway for modulating mental health, as spiritual experiences can promote sustained well-being and psychological resilience.

https://www.ncbi.nlm.nih.gov/pubmed/26231498

13) Psilocybin decreased the threat-induced modulation of top-down connectivity from the amygdala to primary visual cortex, speaking to a neural mechanism that might underlie putative shifts towards positive affect states after psilocybin administration. These findings may have important implications for the treatment of mood and anxiety disorders.

https://www.ncbi.nlm.nih.gov/pubmed/26909323

14) All trials demonstrated reductions in psychiatric rating scale scores or increased response and remission rates. There were large effect sizes related to improved depression and anxiety symptoms. Psilocybin may also potentially reduce alcohol or tobacco use and increase abstinence rates in addiction.

https://www.ncbi.nlm.nih.gov/pubmed/28481178

15)These findings raise the possibility that research into psychedelics might identify novel therapeutic mechanisms and approaches that are based on glutamate-driven neuroplasticity.

https://www.ncbi.nlm.nih.gov/pubmed/20717121

16) The ability of these medicinal tools to treat a range of addictive, psychiatric, and existential disorders is remarkable in scope and possibility. They truly represent a potential paradigmatic shift within the field of psychiatry, too interesting to not explore further.

https://www.ncbi.nlm.nih.gov/pubmed/22640760

17) Sewell, R. A., Halpern, J. H., & Pope, H. G. (2006). Response of cluster headache to psilocybin and LSD. Neurology, 66(12), 1920-1922.

18) Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of general psychiatry, 68(1), 71-78.

19) Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P. C. R., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. Journal of Psychopharmacology, 29(3), 289-299.

20) GREAT ARTICLE: https://www.businessinsider.nl/psychedelics-depression-anxiety-alcoholism-mental-illness-2017-1/?international=true&r=US

21) Metabolism of Psilocybin and Psilocin.

https://www.tandfonline.com/doi/full/10.1080/03602532.2016.1278228

22) Psychedelics promote structural and functional neural plasticity.

https://www.cell.com/cell-reports/pdf/S2211-1247(18)30755-1.pdf

23) Magic mushrooms can increase Neuronal Homological Scaffolding, which promotes a more expansive interconnectedness of individual neurons and different areas of the brain.

http://rsif.royalsocietypublishing.org/content/11/101/20140873

Screen Shot 2018-11-07 at 3.55.31 PM.png

24) Magic mushrooms, LSD and methylphenidate obtained relatively low scores (0.45-0.65) for physical harm, whereas relatively high scores were given for heroin (2.09), crack (2.32), alcohol (2.13) and tobacco (2.10). For cannabis, tobacco, and alcohol the estimated societal disease burden was higher than at individual level.

https://www.ncbi.nlm.nih.gov/pubmed/23542091

25) The CAM concluded that the physical and psychological dependence potential of magic mushrooms was low, that acute toxicity was moderate, chronic toxicity low and public health and criminal aspects negligible.

https://www.ncbi.nlm.nih.gov/pubmed/21256914

26) One comment on the academic journal NCBI claimed magic mushrooms could cause renal (kidney) failure. This is a fallacy due to the fact that, at least in virtue with their true divine purpose, hallucinogenic mushrooms, as any other natural psychoactive substance should not be consumed regularly. (Any synthetic man-made drug should not be consumed under any circumstances, regardless of pharmaceutical or street origin.) The rapid tolerance increase after consumption illustrates this purpose physically. Many people only experience a mushroom trip a handful of pivotal times in their lives, as it was ancestrally, making it impossible for any of the few mycotoxins in edible magic mushrooms to have prolonged harmful effects. Furthermore, the comment was associating the highly poisonous effects of Cortinarius speciosissimus; a non-edible, non-hallucinogenic and highly poisonous mushroom that resembles a gourmet edible mushroom. Thus the argument that one of the most widely consumed edible hallucinogenic mushrooms impairs renal function is unsubstantiated. The identification of hallucinogenic mushrooms is in most cases unnecessary due to modern and industrial fungal/mycelial cultivation methods.

(Claim) https://www.bmj.com/content/345/bmj.e6388.long

Magic mushrooms do not cause renal failure:

https://www.bmj.com/content/345/bmj.e6893.full

Screen Shot 2018-11-07 at 3.55.31 PM.png

27) Divinatory use of Amanita muscaria in North America.

https://www.ncbi.nlm.nih.gov/pubmed/392115

28) Magic AMANITA Mushroom Poisoning  (NOT PSILOCYBIN CUBENSIS)

https://www.ncbi.nlm.nih.gov/pubmed/28189696

30) THE ONLY REPORTED INSTANCE OF MAGIC P. CUBENSIS POISONING:

A man with a severe hepatatis-C infection consumed AMOUNT AND THOSE WITH HEPATITIS-C ARE VULNERABLE TO MYCOTOXINS; THIS IS A SPECIAL CASE AND ALSO SUPPORTS THE SAFETY OF P. CUBENSIS AND OTHER PSILOCYBIN-CONTAINING MUSHROOMS. Hepatitis C is a disease that impairs the livers ability to fight off infection and causes chronic hepatic inflammation, so any mycotoxins, regardless of their safety for normal people, that enter this chaos can and will do some harm, because the antioxidants dedicated to slow hepatic inflammation and oxidative damage are being used to combat the Hep-C virus. In conclusion, the only instances where the consumption of magic mushrooms should be questioned for those infected with Hep-C.

https://www.ncbi.nlm.nih.gov/pubmed/16276262

31) ONE CASE OF UNIDENTIFIED MAGIC MUSHROOM POISONING:

The man was a 28-year old alcoholic with a history of drug abuse, and he was admitted to the hospital multiple times for different drugs and symptoms. Also the only account that tells us he was on mushrooms was himself. This is highly inconclusive and does not indicate a connection between P. Cubensis consumption and true intoxication, not to mention he likely had much more than the agreed upon normal dose.

https://www.ncbi.nlm.nih.gov/pubmed/18926381